Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath

Business Resilience Business Resilience Quality & Excellence Responsible Operations Stakeholder Centricity "At Piramal Pharma, sustainability is not just a responsibility — it is a deliberate choice that defines the way we operate and the way we grow. In today's complex environment, shaped by climate change, regulatory shifts, and rising expectations of transparency and ethical conduct, sustainability has become central to long-term value creation. This year, we have...

MUMBAI, India, 26/08/2025 (informazione.news - comunicati stampa - salute e benessere)

—

As a part of its overall sustainability initiatives, in FY 2025, PPL in collaboration with Piramal Foundation advanced its CSR initiatives across , with a strong focus on education, community well-being, and women's empowerment. In FY2025, the Company invested in programmes that upgraded school infrastructure, enhanced teaching capacity, and improved learning outcomes, while also addressing public health and safe water practices. Employee volunteering further amplified impact through initiatives such as plantation drives, health awareness campaigns, and community immersion projects. Additionally, PPL partnered with the Life Sciences Sector Skill Development Council to launch a near its Digwal plant and continued its support of the , aimed at improving the lives of in underserved regions by 2047.

The Sustainability report follows GRI standards and is aligned with SASSB and UNGC frameworks, underscoring PPL's commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement. For more information, please refer to the full report available at https://www.piramalpharma.com/assets/download/Piramal-Pharma-Sustainability-Report-fy-2025.pdf.

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

Logo: https://mma.prnewswire.com/media/2538752/5476839/Piramal_Pharma_Limited_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-publishes-fy2025-sustainability-report-outlining-performance-and-decarbonization-glidepath-302538736.html